Patent US2896729A successfully refreshed from Google Patents.
US5626862A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Controlled local delivery of chemotherapeutic agents for treating solid tumors
Assignee: Johns Hopkins University
•
Filing: 1994-08-02
•
Granted: 1997-05-06
•
Expires: 2014-08-02
Abstract
Abstract A method and devices for localized delivery of a chemotherapeutic agent to solid tumors, wherein the agent does not cross the blood-brain barrier and is characterized by poor bioavailability and/or short half-lives in vivo, are described. The devices consist of reservoirs which release drug over an extended time period while at the same time preserving the bioactivity and bioavailability of the agent. In the most preferred embodiment, the device consists of biodegradable polymeric matrixes, although reservoirs can also be formulated from non-biodegradable polymers or reservoirs connected to implanted infusion pumps. The devices are implanted within or immediately adjacent the tumors to be treated or the site where they have been surgically removed. The examples demonstrate the efficacy of paclitaxel and camptothecin delivered in polymeric implants prepared by compression molding of biodegradable and non-biodegradable polymers, respectively. The results are highly statistically significant.
Inventors
- 👤 Henry Brem
- 👤 Robert S. Langer
- 👤 Abraham J. Domb
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 17:06
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0085; A61K31/00; A61K31/33; A61K31/335; A61K31/337; A61K31/395; A61K31/435; A61K31/47; A61K31/4738; A61K31/4745; A61K31/555; A61K9/20; A61K9/2004; A61K9/2022; A61K9/2027; A61K9/2031; A61K9/204; A61P; A61P35/00
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
75 words
A chemotherapeutic composition comprising a biocompatible polymeric matrix and a water insoluble, lipid insoluble chemotherapeutic agent, which does not cross the blood-brain barrier, wherein the agent is incorporated into and released from the polymeric matrix by degradation of the matrix or diffusion of the agent out of the matrix over a period of time of at least eight hours in an amount effective to inhibit growth of a solid tumor when administered to the tumor.
Claim 2
Dependent Claim
75 words
A chemotherapeutic composition comprising a biocompatible polymeric matrix and a water insoluble, lipid insoluble chemotherapeutic agent, which does not cross the blood-brain barrier, wherein the agent is incorporated into and released from the polymeric matrix by degradation of the matrix or diffusion of the agent out of the matrix over a period of time of at least eight hours in an amount effective to inhibit growth of a solid tumor when administered to the tumor.
Claim 3
Dependent Claim
11 words
The composition of claim 1 wherein the chemotherapeutic agent is paclitaxel.
Claim 4
Dependent Claim
11 words
The composition of claim 1 wherein the chemotherapeutic agent is camptothecin.
Claim 5
Dependent Claim
11 words
The composition of claim 1 wherein the polymer matrix is biodegradable.
Claim 6
Dependent Claim
34 words
The composition of claim 4 wherein the polymeric matrix is formed of a polymer selected from the group consisting of polyanhydrides, polyhydroxy acids, polyphosphazenes, polyorthoesters, polyesters, polyamides, polysaccharides, polyproteins and copolymers and blends thereof.
Claim 7
Dependent Claim
15 words
The composition of claim 1 wherein the polymeric matrix is formed of ethylene vinyl acetate.
Claim 8
Dependent Claim
33 words
The composition of claim 1 further comprising additional biologically active compounds selected from the group consisting of chemotherapeutics, antibiotics, antivitals, antiinflammatories, cytokines, immunotoxins, anti-tumor antibodies, anti-angiogenic agents, anti-edema agents, radiosensitizers, and combinations thereof.
Claim 9
Independent Claim
79 words
A method of administering to a patient in need of treatment a water insoluble, lipid insoluble chemotherapeutic agent comprising administering the chemotherapeutic agent locally adjacent or in a solid tumor, wherein the agent is incorporated into and released from a polymeric matrix by degradation of the polymer matrix or diffusion of the agent out of the matrix over a period of time of at least eight hours, wherein in an amount effective to inhibit growth of the solid tumor.
Claim 10
Independent Claim
79 words
A method of administering to a patient in need of treatment a water insoluble, lipid insoluble chemotherapeutic agent comprising administering the chemotherapeutic agent locally adjacent or in a solid tumor, wherein the agent is incorporated into and released from a polymeric matrix by degradation of the polymer matrix or diffusion of the agent out of the matrix over a period of time of at least eight hours, wherein in an amount effective to inhibit growth of the solid tumor.
Claim 11
Dependent Claim
11 words
The method of claim 8 wherein the chemotherapeutic agent is paclitaxel.
Claim 12
Dependent Claim
11 words
The method of claim 8 wherein the chemotherapeutic agent is camptothecin.
Claim 13
Dependent Claim
18 words
The method of claim 8 wherein the chemotherapeutic agent is locally delivered by direct infusion to the tumor.
Claim 14
Dependent Claim
23 words
The method of claim 8 wherein the chemotherapeutic agent is locally delivered by implantation of the biocompatible polymer matrix incorporating the chemotherapeutic agent.
Claim 15
Dependent Claim
11 words
The method of claim 12 wherein the polymer matrix is biodegradable.
Claim 16
Dependent Claim
34 words
The method of claim 13 wherein the polymeric matrix is formed of a polymer selected from the group consisting of polyanhydrides, polyhydroxy acids, polyphosphazenes, polyorthoesters, polyesters, polyamides, polysaccharides, polyproteins, and copolymers and blends thereof.
Claim 17
Dependent Claim
15 words
The method of claim 12 wherein the polymeric matrix is formed of ethylene vinyl acetate.
Claim 18
Dependent Claim
14 words
The method of claim 8 further comprising administering radiation in combination with the composition.
Claim 19
Dependent Claim
38 words
The method of claim 8 further comprising administering with the chemotherapeutic agent additional biologically active compounds selected from the group consisting of chemotherapeutics, antibiotics, antivitals, antiinflammatories, cytokines, immunotoxins, anti-tumor antibodies, anti-angiogenic agents, anti-edema agents, radiosensitizers, and combinations thereof.
Claim 20
Dependent Claim
21 words
The method of claim 8 wherein the composition is in the form of micro-implants and are administered by injection or infusion.
References Cited (Backward Citations)
US4888176A
Cited
US4757128A
Cited
US4789724A
Cited
US4867978A
Cited
US4857311A
Cited
US4943579A
Cited
US5064823A
Cited
US5225404A
Cited
US5145684A
Cited
US5362831A
Cited
US5380751A
Cited
US5395850A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-05-05 | 2000-11-04 | 2001-05-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-05-05 | 2004-11-04 | 2005-05-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-05-05 | 2008-11-04 | 2009-05-06 | $7700.00 | Window Closed / Lapsed |